title: Angiotensin-converting enzyme inhibitor versus calcium antagonist in the treatment of hypertension.
abstract: Sixteen patients with essential hypertension were treated for 2 consecutive 6-week periods with either the angiotensin-converting enzyme (ACE) inhibitor enalapril (20 mg once daily) or the calcium antagonist diltiazem (120 mg twice daily). The sequence of the treatment phases was randomly allocated. Blood pressure decreased from 154/102 +/- 5/2 mm Hg (mean +/- SEM) to 135/96 +/- 4/2 and 140/98 +/- 3/2 mm Hg during treatment with enalapril and diltiazem, respectively. It was impossible in the individual hypertensive patient to predict the long-term blood pressure response to one of the agents studied based on the long-term blood pressure response to the other agent.
authors.affiliation: Division of Nephrology and Hypertension, Centre Hospitalier Universitaire, Lausanne, Switzerland.
authors.forename: H R
authors.initials: HR
authors.lastname: Brunner
authors.forename: J
authors.initials: J
authors.lastname: Bidiville
authors.forename: G
authors.initials: G
authors.lastname: Waeber
authors.forename: M
authors.initials: M
authors.lastname: Porchet
authors.forename: J
authors.initials: J
authors.lastname: Nussberger
authors.forename: B
authors.initials: B
authors.lastname: Waeber
mesh_terms: D000328:Adult; D001794:Blood Pressure / Q000187:drug effects; D004110:Diltiazem / Q000627:therapeutic use*; D004656:Enalapril / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D006973:Hypertension / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged
chemical_list: D004656:Enalapril; D004110:Diltiazem